Loading...
•
Jun 30, 2024
C4 Therapeutics Q2 2024 Earnings Report
C4 Therapeutics reported financial results for the second quarter ended June 30, 2024, and recent business highlights.
Key Takeaways
C4 Therapeutics reported a net loss of $17.7 million for Q2 2024, with total revenue of $12.0 million. The company's cash, cash equivalents, and marketable securities totaled $295.7 million as of June 30, 2024, expected to fund operations into 2027.
Advanced the Phase 1/2 Clinical Trial of Cemsidomide in R/R MM and R/R NHL, continuing to enroll patients.
Advanced the Phase 1/2 Clinical Trial of CFT1946 for BRAF V600X mutant solid tumors, continuing to enroll patients.
Preliminary CFT1946 monotherapy data accepted as a mini oral presentation at the ESMO Congress 2024.
Ron Cooper was appointed as chairman of C4T’s Board of Directors in June 2024.
Revenue by Segment
Forward Guidance
C4T expects that its cash, cash equivalents and marketable securities as of June 30, 2024 will be sufficient to fund planned operating expenses and capital expenditures into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...